Acute Ischemic Stroke Market will reach at US$ 19,385.3 Mn by 2032, Size, Development Data, Growth Analysis & Forecast 2022 to 2028 -Bayer, Boehringer Ingelheim, Roche, Sanofi, Biogen, Daiichi Sankyo, Pfizer

The global acute ischemic stroke (AIS) market is estimated to be valued at US$ 8,921.2 million in 2021 and is expected to increase to US$ 19,385.3 Mn by 2032, witnessing a CAGR of 4.12% over the forecast period (2021-2032).

Acute Ischemic Stroke market competition by TOP Players are: Bayer, Boehringer Ingelheim, Roche, Sanofi, Biogen, Daiichi Sankyo, Pfizer

Get Free Sample PDF including full TOC, Tables and Figures and Available customizations) in Acute Ischemic Stroke: https://www.mraccuracyreports.com/report-sample/384978

Increasing prevalence of ischemic stroke globally is expected to drive the growth of the global acute ischemic stroke (AIS) market.

For instance, as per the 2021 Heart Disease & Stroke Statistical Update Fact Sheet provided by the American Heart Association, the global prevalence of stroke in 2019 was 101.5 million people, while that of ischemic stroke was 77.2 million. Overall, age-standardized stroke prevalence rate in 2019 was highest in Oceania, Southeast Asia, North Africa, and the Middle East, as well as East Asia. Countries in parts of North Africa and the Middle East, Southern sub-Saharan Africa, high-income countries in North America and Southeast Asia had the highest ischemic stroke prevalence rate. Furthermore, in 2019, there were 6.6 million deaths worldwide due to cerebrovascular diseases. In 2019, a total of 3.3 million people worldwide died from ischemic stroke, 2.9 million died from intracerebral hemorrhage, and 0.4 million died from subarachnoid hemorrhage.

In the context of the coronavirus (COVID-19) global pandemic caused by SARS-CoV-2, a possible link between this disease and stroke has been proposed. Between March 24, 2020 and July 17, 2020, PCR-confirmed COVID-19 patients with ischemic stroke were admitted to an academic health system in metropolitan Atlanta, Georgia (U.S.). 13 (2.5%) of 396 ischemic stroke patients admitted during this study period were also diagnosed with COVID-19. Each of the 13 patients had at least one stroke-related co-morbidity. The most common type of ischemic stroke was embolic, with four cases explained by atrial fibrillation. During the study period, COVID-19 patients had a significantly higher rate of cryptogenic stroke than non-COVID-19 patients.

Global Acute Ischemic Stroke (AIS) Market: Restraint

High cost of treatment and lack of transparent reimbursement policies is expected to restrain the market growth over the forecast period. For instance, according to an article published by National Center for Biotechnology Information (NCBI), published in August 2018, the average in-hospital cost per acute stroke patient was approximately US$ 6961 ± 15,663 in Lebanon. Cost determinants were length of hospital stay, length of intensive care unit stay, stroke type, stroke severity, modified Rankin scale, third-party payers, operations, and infectious complications.

Access full Report Description, TOC, Table of figures, Chart, etc: https://www.mraccuracyreports.com/reportdetails/reportview/384978

The market share (by revenue) for the public players will be based on the information available in the public domain, and for the private players, such information will be provided on best effort basis, which will entirely be based on primary interviews and latest developments of the companies

On the basis of product, the Acute Ischemic Stroke market research displays the revenue, price, market share and growth rate of each type, primarily split into,

Antihypertensive Therapeutics, Antiplatelet Therapeutics, Anticoagulants.

On the basis of the end users, the Acute Ischemic Stroke market research focuses on the status and outlook for major applications, consumption (sales), market share and growth rate for each application, including

Hospitals, Ambulatory Surgical Center, Diagnostic Centers

Key Market Takeaways:

The global acute ischemic stroke (AIS) market is expected to exhibit a CAGR of 4.0% during the forecast period, owing to the new product launches by key players in the global market. For instance, Medtronic plc., (an American-Irish registered medical device company) announced the launch of its Solitaire (TM) X revascularization device in the U.S. used for the treatment of acute ischemic stroke. The Solitaire X device mechanically removes blood clots from blocked vessels in the brain to restore blood flow in patients suffering from acute ischemic stroke with occlusion of large vessels.

Among regions, North America dominates the global acute ischemic stroke (AIS) market, due to the advent of genomic medicine, and a strong product pipeline in the region. Moreover the U.S. and Canada are the key markets for acute ischemic stroke therapeutics market in North America.
North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Book this market research study Acute Ischemic Stroke Market - Global Outlook and Forecast 2022-2028 @ https://www.mraccuracyreports.com/checkout/384978

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Call Us - UK +44 7452119323
USA +1 8045001224
Email us - sales@mraccuracyreports.com
30 Crawley Lane, West Sussex, RH10 7EG, United Kingdom
3351 Green Turtle Rd, Regina, SK S4V 3N6, Canada

MR Accuracy Reports is a Market Research and consulting company that accomplishes requirement of research agencies,small, medium and large corporations, global business leaders, government organizations,
SME's, Individual & Start-ups, top management consulting firms.

This release was published on openPR.